187 related articles for article (PubMed ID: 17973263)
1. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.
Santinelli A; Pisa E; Stramazzotti D; Fabris G
Int J Cancer; 2008 Mar; 122(5):999-1004. PubMed ID: 17973263
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
3. HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases.
Schoppmann SF; Jesch B; Zacherl J; Wrba F; Hejna M; Maresch J; Langer FB; Riegler MF; Pluschnig U; Birner P
Br J Surg; 2011 Oct; 98(10):1408-13. PubMed ID: 21618213
[TBL] [Abstract][Full Text] [Related]
4. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
5. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
6. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas.
Regitnig P; Schippinger W; Lindbauer M; Samonigg H; Lax SF
J Pathol; 2004 Aug; 203(4):918-26. PubMed ID: 15258994
[TBL] [Abstract][Full Text] [Related]
7. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
8. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
9. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer.
Nakayama Y; Nakagomi H; Omori M; Inoue M; Takahashi K; Maruyama M; Takano A; Furuya K; Amemiya K; Ishii E; Oyama T
Breast Cancer; 2016 Jul; 23(4):633-9. PubMed ID: 25968348
[TBL] [Abstract][Full Text] [Related]
10. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of HER2 gene status between primary breast cancer and synchronous axillary lymph node metastasis].
Liu YY; Wu SF; Liang ZY; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):393-6. PubMed ID: 27256047
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study.
Cho EY; Han JJ; Choi YL; Kim KM; Oh YL
J Korean Med Sci; 2008 Dec; 23(6):1053-61. PubMed ID: 19119452
[TBL] [Abstract][Full Text] [Related]
13. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
Guarneri V; Giovannelli S; Ficarra G; Bettelli S; Maiorana A; Piacentini F; Barbieri E; Dieci MV; D'Amico R; Jovic G; Conte P
Oncologist; 2008 Aug; 13(8):838-44. PubMed ID: 18650259
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.
Gancberg D; Di Leo A; Cardoso F; Rouas G; Pedrocchi M; Paesmans M; Verhest A; Bernard-Marty C; Piccart MJ; Larsimont D
Ann Oncol; 2002 Jul; 13(7):1036-43. PubMed ID: 12176781
[TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
17. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K; Kamio T; Nishikawa T; Kameoka S
Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
[TBL] [Abstract][Full Text] [Related]
18. Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis.
Santiago MP; Vázquez-Boquete A; Fernández B; Masa C; Antúnez JR; Fraga M; Forteza J; García-Caballero T
Histol Histopathol; 2009 Jun; 24(6):675-82. PubMed ID: 19337966
[TBL] [Abstract][Full Text] [Related]
19. HER2 gene status in primary breast cancers and matched distant metastases.
Tapia C; Savic S; Wagner U; Schönegg R; Novotny H; Grilli B; Herzog M; Barascud AD; Zlobec I; Cathomas G; Terracciano L; Feichter G; Bubendorf L
Breast Cancer Res; 2007; 9(3):R31. PubMed ID: 17511881
[TBL] [Abstract][Full Text] [Related]
20. Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence.
Jeschke U; Mylonas I; Kunert-Keil C; Dazert E; Shabani N; Werling M; Kuhn C; Janni W; Gerber B; Friese K
Oncol Rep; 2005 Mar; 13(3):413-9. PubMed ID: 15706409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
